Evgeny Krynetskiy

发表

Genetic variation and individualized medicine.

J. Driban, A. Mishra, M. Higgins, 2010, Journal of sport rehabilitation.

ASSESSMENT OF CANDIDATE GENE POLYMORPHISMS AS BIOMARKERS FOR PELVIC PAIN SYNDROME

M. Pontari, J. Gaughan, S. Chuai, 2013 .

Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells

J. Downing, M. Relling, Cheng Cheng, 2011, Nature Medicine.

Accelerated cellular senescence phenotype of GAPDH-depleted human lung carcinoma cells.

A. Mishra, N. Krynetskaia, Evgeny Krynetskiy, 2011, Biochemical and biophysical research communications.

Is RNA Binding in the Rossmann Fold Essential for GAPDH Intranuclear Functions

N. Krynetskaia, Evgeny Krynetskiy, Manali Phadke, 2016 .

INSTRUCTIONAL DESIGN AND ASSESSMENT Introducing Pharmacy Students to Pharmacogenomic Analysis

Evgeny Krynetskiy, I. Calligaro, 2009 .

Clinical Response and Side Effects of Metoclopramide: Associations With Clinical, Demographic, and Pharmacogenetic Parameters

J. Gaughan, H. Parkman, A. Mishra, 2012, Journal of clinical gastroenterology.

Determining Candidate Single Nucleotide Polymorphisms in Acquired Laryngotracheal Stenosis

A. Soliman, N. Krynetskaia, Mursalin M. Anis, 2018, The Laryngoscope.

Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage

N. Krynetskaia, Evgeny Krynetskiy, Sachin H Jadhav, 2009, Molecular Cancer Therapeutics.

Disruption of NAD(+) binding site in glyceraldehyde 3-phosphate dehydrogenase affects its intranuclear interactions.

S. Merali, S. Gothe, A. Mishra, 2015, World journal of biological chemistry.

High Mobility Group Protein B1 Is an Activator of Apoptotic Response to Antimetabolite Drugs

S. Vucetic, Z. Obradovic, H. Xie, 2008, Molecular Pharmacology.

RUNNING TITLE PAGE Running title : HMGB 1 is an activator of apoptosis caused by chemotherapy

S. Vucetic, Z. Obradovic, H. Xie, 2007 .

Establishing a model for assessing DNA damage in murine brain cells as a molecular marker of chemotherapy-associated cognitive impairment.

N. Krynetskaia, E. Walker, Evgeny Krynetskiy, 2013, Life sciences.

Cytotoxicity of chemotherapeutic agents in glyceraldehyde-3-phosphate dehydrogenase-depleted human lung carcinoma A549 cells with the accelerated senescence phenotype

N. Krynetskaia, Evgeny Krynetskiy, Manali Phadke, 2013, Anti-cancer drugs.

Glyceraldehyde 3-Phosphate Dehydrogenase Depletion Induces Cell Cycle Arrest and Resistance to Antimetabolites in Human Carcinoma Cell Lines

A. Mishra, N. Krynetskaia, Evgeny Krynetskiy, 2009, Journal of Pharmacology and Experimental Therapeutics.

Genetic findings in sport-related concussions: potential for individualized medicine?

J. McDevitt, Evgeny Krynetskiy, 2017, Concussion.

Neuronal structural protein polymorphism and concussion in college athletes

J. Driban, M. Higgins, R. Tierney, 2011, Brain injury.

Apolipoprotein E Genotype and Concussion in College Athletes

J. Gaughan, M. Higgins, R. Tierney, 2010, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication.

A. Wallqvist, S. Chaudhury, M. AbdulHameed, 2014, Bioorganic & medicinal chemistry.

Beyond SNPs and CNV: Pharmacogenomics of Polymorphic Tandem Repeats

Evgeny Krynetskiy, 2017 .

Pharmacogenomics of Simple Repeats: How Do You Solve a Problem like VNSR?

Evgeny Krynetskiy, Evgeny Krynetskiy, 2014 .

Introducing pharmacy students to pharmacogenomic analysis.

Evgeny Krynetskiy, Ina Lee Calligaro, 2009, American journal of pharmaceutical education.

Building Individualized Medicine: Prevention of Adverse Reactions to Warfarin Therapy

Evgeny Krynetskiy, P. McDonnell, Patrick McDonnell, 2007, Journal of Pharmacology and Experimental Therapeutics.

Development of a Behavioral and Imaging Model of Feeding in Planarians

R. Raffa, S. Patel, S. Rawls, 2012 .

Genetic variation in SLC17A7 promoter associated with response to sport-related concussions

J. Gaughan, R. Tierney, David J. Hayes, 2016, Brain injury.

Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects

J. Gaughan, H. Parkman, A. Mishra, 2010, Digestive Diseases and Sciences.

The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7

H. Brauch, M. Schwab, W. Schroth, 2013, Drug Metabolism and Disposition.

Association between GRIN2A promoter polymorphism and recovery from concussion

J. Gaughan, R. Tierney, J. Torg, 2015, Brain injury.

Translational genomics of acquired laryngotracheal stenosis

A. Soliman, J. Khurana, Mursalin M. Anis, 2014, The Laryngoscope.

Quantitative study of renormalization transformation method to correct the inhomogeneity in MR images

Qing Ji, Wilburn E. Reddick, John O. Glass, 2002, SPIE Medical Imaging.

High Mobility Group Protein B1 Is an Activator of Apoptotic Response to Antimetabolite Drugs

S. Vucetic, Z. Obradovic, H. Xie, 2008 .

Are glycyrrhizin derivatives specific inhibitors of HMGB1/DNA interactions

N. Krynetskaia, Evgeny Krynetskiy, D. Canney, 2011 .

DNA microarray SNP associations with clinical efficacy and side effects of domperidone treatment for gastroparesis

H. Parkman, Evgeny Krynetskiy, Zoran Obradovic, 2012, J. Biomed. Informatics.

Dna Microarray Snp Associations with Clinical Efficacy and Side Effects of Domperidone Treatment for Gastroparesis

Zoran Obradovic, Dairong Wang, Henry P. Parkman, 2022 .

Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication.

A. Wallqvist, M. AbdulHameed, F. Sharom, 2014, Bioorganic & medicinal chemistry.